Name | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e |
---|---|---|---|---|---|---|
KGV | 34,15 | 94,19 | 32,69 | 17,220 | 32,19 | 19,970 |
KCV | 8,5600 | 12,090 | 9,3600 | 6,0000 | 7,4700 | - |
KUV | 2,5700 | 3,1900 | 2,4500 | 1,3900 | 1,5600 | - |
Dividende | - | - | - | - | - | 1,8500 |
Dividendenrendite | - | - | - | - | - | 2,8700 |
Marktkapitalisierung | 3,46 Mrd. |
Name | 2022 | 2023 | 2024 |
---|---|---|---|
Kurs-Gewinn-Verhältnis | 13,498 | 20,638 | 21,178 |
Kurs-Cashflow-Verhältnis | 20,617 | 12,005 | 21,800 |
Kurs-Umsatz-Verhältnis | 149,10 | 32,66 | 3,9460 |
Dividendenrendite in % | 2,1851 | 1,5904 | 2,0000 |
Name | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e |
---|---|---|---|---|---|---|
Gewinn je Aktie | 2,1100 | 0,8600 | 2,1200 | 2,5300 | 1,6700 | 3,1900 |
Cashflow | 478,434 Mio. | 380,283 Mio. | 426,458 Mio. | 410,894 Mio. | 401,131 Mio. | - |
Cashflow je Aktie | 8,4200 | 6,7000 | 7,4000 | 7,2600 | 7,2000 | - |
Umsatz je Aktie | 28,02 | 25,39 | 28,24 | 31,30 | 34,36 | - |
Dividende je Aktie | - | - | - | - | - | 1,8500 |
Name | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Eigenkapitalrendite | 19,390 | 10,330 | 25,74 | 30,86 | 21,290 |
Umsatzrendite | 7,5200 | 3,3700 | 7,5100 | 8,0800 | 4,8500 |
Gesamtrendite | 4,0900 | 1,8600 | 4,4900 | 5,2000 | 3,0700 |
Name | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Anlagenintensität | 88,00 | 88,00 | 87,00 | 86,00 | 87,00 |
Arbeitsintensität | 12,000 | 12,000 | 13,000 | 14,000 | 13,000 |
Eigenkapitalquote | 21,080 | 17,960 | 17,460 | 16,840 | 14,410 |
Fremdkapitalquote | 78,59 | 81,78 | 82,20 | 82,81 | 85,30 |
Verschuldungsgrad | 372,86 | 455,46 | 470,78 | 491,66 | 592,11 |
Name | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Liquidität 1. Grades | 14,000 | 11,000 | 7,0000 | 10,000 | - |
Liquidität 2. Grades | 46,00 | 39,00 | 35,00 | 51,00 | - |
Liquidität 3. Grades | 48,00 | 41,00 | 38,00 | 56,00 | - |
Working Capital | -348,98 Mio. | -441,09 Mio. | -594,90 Mio. | -303,10 Mio. | -443,40 Mio. |
negativ | neutral | positiv |